Company: NCEL
Filing Date: 2025-11-06
Form Type: POS AM
Source: 0001213900-25-106799
Chunk: 6

Company: NewcelX Ltd.
Filing Date: 2025-11-06
Form: POS AM
Chunk 6
---
imastem’s competitors and industry; •NLS’s and Kadimastem’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; •expectations regarding the time during which NLS will be an EGC under the JOBS Act; •NLS’s and Kadimastem’s future capital requirements and sources and uses of cash; •NLS’s and Kadimastem’s ability to obtain funding for their operations; •NLS’s and Kadimastem’s business, expansion plans and opportunities; •NLS’s and Kadimastem’s management and board of directors; 2 •the listing of NLS’s securities on Nasdaq; •geopolitical risk and changes in applicable laws or regulations; •fluctuations in exchange rates between the foreign currencies in which NLS and Kadimastem typically do business and the United States dollar; and •the outcome of any known and unknown litigation and regulatory proceedings. The foregoing list is intended to identify only certain of the principal factors that could cause actual results to differ. For a more detailed description of the risks and uncertainties affecting our company, reference is made to the Annual Report, which was filed with the SEC, on May 16, 2025, and the other risk factors discussed from time to time by our company in reports filed or furnished to the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward -lookingstatements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. All information included herein relating to shares or price per share reflects the 1 -for-40reverse split effected by us on September 27, 2024. Unless otherwise indicated, “we,” “us,” “our,” the “Company” and “NLS” refer to NewcelX Ltd. and its wholly owned subsidiary, NLS Pharmaceutics Inc., a Delaware corporation. Overview We are an emerging biopharmaceutical company engaged in the discovery and development of life -improvingdrug therapies to treat rare and complex CNS disorders who have unmet medical needs. Our lead compound mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy (lead indication) and ADHD (follow -onindication). We believe that this dual mechanism of action will also enable Mazindol ER to